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for the product A and 40% for the product B and were asked for their 
willingness to pay for product A. 
Results: At this time, 31 patients had been enrolled: men: 20 (64,5%), 
age: 64,5 ± 11,7 years, hairless: 4 (13%). In analogical visual scale, 
the impact of alopecia were assessed at 4,7 ± 3,5, median: 5. The mean 
amount patients were willing to pay by 3-week chemotherapy cycle is 
83,3 ± 141,7 euros (median 12,5 euros); 12 (38,7%) of the patients are 
not ready to pay for the product A. 
Discussion and Conclusion: complete results and analysis in rela-
tion with the willingness to pay stratiﬁed by sex, age, employment and 
income will be presented at the meeting. 
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Background: There are few data on the economic consequences of 
targeted cancer therapies. 
Objective: This study examined care consumption and management 
costs among patients who received second- or third-line oral erlotinib 
therapy for non small-cell lung cancer (NSCLC). 
Methods: The study involved two observational cohorts of NSCLC 
second- or third-line treated patients. In the ﬁrst, created in 2005 (be-
fore erlotinib became available), the patients received IV chemotherapy 
alone (IV cohort, 233 patients), while the patients in the second cohort, 
created in 2006, received oral erlotinib (oral cohort, 166 patients). Only 
direct costs were taken into account (drug acquisition and administra-
tion, hospitalization, consultation, costs of managing common toxici-
ties). The analysis adopted the payer’s perspective. 
Results: Treatment lasted a similar length in the IV and oral cohorts 
during second-line treatment (94.5 ± 67.5 and 105 ± 79.4 days, p = 
0.07) but was signiﬁcantly longer in the oral cohort during third-line 
therapy line (76.6 ± 96.5 versus and 114.4 ± 74.5 days, p < 0.008). 
There were more women in the oral cohort (41% versus 26.2%, 
p=0.023) and a higher rate of adenocarcinoma (60.8% versus 47.2%, 
p = 0.0043). There was no difference in smoking status or the disease 
stage at diagnosis. Likewise, the rate of conventional hospitalization 
was not different between the two cohorts. In contrast, during 100 days 
of management, the patients in the oral cohort tended to spend less time 
in hospital during second-line treatment (3 ± 6.6 vs 7.7 ± 18.3 days, p = 
0,057), and the difference was statistically signiﬁcant during third-line 
treatment (4.8 ± 11.7 vs 8.7 ± 14 days, p<0.05). Regardless of the line 
of treatment, the oral cohort made signiﬁcantly fewer stays in daycare 
clinics (p<0.001), and received signiﬁcantly less antiemetic treatment 
(p<0.0001), erythropoietin (p<0.005) and G-CSF (p< 0001). In con-
trast, these patients required more treatment for skin rash (p<0.001). 
Monthly management costs per patient in the IV and oral cohorts were 
respectively 3126 and 2750 euros during second-line treatment and 
3026 and 2823 euros during third-line treatment (no signiﬁcant differ-
ence). A sensitivity analysis showed that the results in the IV cohort 
were dependent on the cost of chemotherapy. 
Discussion: One limit of this study is that transport costs were not 
taken into account. Conclusion: In oral cohort, the cost of Erlotinib 
is compensated by the reduction of daycare hospitalization costs and 
the limited cost of medication to treat adverse events compared to IV 
chemotherapy such as erythropoietin or G-CSF. 
Conclusion: These results must be validated by prospective observa-
tional studies focusing on quality of life and the time spent in hospital. 
This study was supported by Roche Pharma France
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Introduction: A prospective cohort study was undertaken to develop 
risk models for neutropenic complications (NC) consisting of severe or 
febrile neutropenia (FN) among cancer patients receiving chemothera-
py. Models are presented of the risk of such events among lung cancer 
patients initiating a new chemotherapy regimen. 
Methods: Of 907 lung cancer patients, data on 1 or more cycles of che-
motherapy were available on 863 lung cancer patients (665 non small 
cell lung cancer [NSCLC] and 198 small cell lung cancer [SCLC]) 
initiating a new chemotherapy regimen at 115 randomly selected 
U.S. oncology practice sites. Univariate and multivariate proportional 
hazards regression analyses were undertaken to assess the time from 
treatment initiation to the initial NC up to 4 cycles of chemotherapy. In 
the absence of events, patients were censored at the last time seen. 
Results: Of the 863 patients with data on at least 1 cycle of chemo-
therapy, NC (or FN) was experienced over a median of 3 cycles in 15% 
(5%) with NSCLC and over a median of 4 cycles in 40% (18%) with 
SCLC. Four evaluable cycles of treatment were completed in 45% and 
58% of patients with NSCLC and SCLC, respectively. Independent 
clinical risk factors for NC in patients with NSCLC include: leukopenia 
(hazard ratio [HR]=2.1); hyperglycemia (HR=1.8); elevated bilirubin 
(HR=2.6) and alkaline phosphatase (HR=1.7); recent surgery (HR=1.8) 
or chemotherapy (HR=2.9); regimens incoporating cisplatin or carbopl-
atin (HR=4.9), docetaxel (HR=2.2), gemcitabine (HR=2.8), or vinorel-
bine (HR=5.1); planned relative dose intensity >85% (HR=1.8) while 
prophylactic myeloid growth factor was associated with a signiﬁcant 
decrease in risk (HR=0.40). Alternatively, signiﬁcant independent risk 
factors for NC among patients with SCLC include: elevated bilirubin 
(HR=3.9); concurrent immunosuppressives (HR=2.0); regimen based 
on topoisomerase inhibitors (HR=5.1) and age >65 years (HR=1.9) 
and thrombocytopenia (HR=3.4) while reduced risk was observed with 
growth factor prophylaxis (HR=0.41). Model ﬁt for both models was 
excellent by a likelihood ratio test (P<.0001). 
Conclusions: Multivariate analysis for NC identiﬁes overlapping as 
well as distinct risk factors for patients with NSCLC and SCLC receiv-
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ing systemic chemotherapy. Such risk models may have applicability in 
identifying patients at increased risk for early NC. Independent valida-
tion of these models will be conducted in a separate population of lung 
cancer patients.
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In 2002 a proposal was made to Macmillan Cancer Relief (now known 
as Macmillan Cancer Support) to support the establishment of Meso-
thelioma UK, the National Macmillan Mesothelioma Resource Centre 
at Glenﬁeld Hospital, Leicester. The Centre opened in 2004. 
Methods: 
The objectives of the centre are:
• To provide high quality, impartial and up-to-date information to all 
UK mesothelioma patients, their carers, health care professionals 
and associated organisations. 
• To provide regional support for ongoing development in the me-
sothelioma ﬁeld through the continued development of a national 
network of trained and experienced nurse specialists. 
• To establish a consultant nurse post to provide overall leadership to 
the work of Mesothelioma UK, including nurse-led research. 
• To work in collaboration with individuals interested in mesothe-
lioma and with interest related groups.
• To explore the feasibility of establishing and developing a network 
of mesothelioma support groups.
• To promote the problems and issues raised by mesothelioma through 
mediums such as articles, conferences and the media.
Results: From the current progress already achieved by the Macmillan 
Mesothelioma UK Project, it can be anticipated that all its objectives 
will be achieved by the end of the three years. The value of services 
provided by Mesothelioma UK on a national level, to the public and to 
health care, can already be demonstrated and is expected to grow. 
Conclusion: This presentation will chart the development of Mesothe-
lioma UK and highlight the achievements and beneﬁts of establishing 
a co-ordinated approach to provide support and information for a rare 
tumour such as mesothelioma.
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Background: The multidisciplinary provincial Lung Disease Site 
Group (LDSG) has met regularly for the past 10 years to develop 
practice guidelines (PGs). Current members include medical (17) and 
radiation (11) oncologists, thoracic surgeons (4) and research coordina-
tors (1). A medical sociologist, patients, pathologists, and nurses have 
participated in speciﬁc PG development activities.
Methods: The LDSG has used the practice guideline (PG) develop-
ment cycle described by Browman GP et al (JCO 1998; 16(3):1226-
31).
Results: 31 reports, including 25 PGs have been published in peer-
reviewed journals and all PG’s are posted on CCO’s website, www.
cancercare.on.ca. Initial guideline topics were selected on the basis of 
known practice variation, controversy in practice, or new and emerging 
data with potential to change practice. PGs for single chemotherapy 
drugs (6) or chemotherapy usage for speciﬁc situations (7) have 
dominated DSG activity and have commonly informed the provincial 
funding decisions that make new and expensive drugs available for 
speciﬁc indications.
5 PGs on radiotherapy alone and 3 on RT as part of combined modality 
therapy (CMT) have been completed. An analysis of fractions used for 
curative radiotherapy in stage III NSCLC by treatment centre suggests 
wide adoption although low numbers of treated patients per Centre 
implies that appropriate patients are either not being referred or co-
morbidities in this patient population preclude the routine application 
of PG recommendation. 
A review of evidence on Positron Emission Tomography (PET) in 
lung cancer supported its use in the assessment of solitary pulmonary 
nodules when other diagnostic tests failed, but provided conﬂicting evi-
dence in relation to its role in the clinical management of early stage, 
potentially resectable (Stage I-IIIa) and locally advanced, inoperable 
NSCLC. As a consequence, two clinical trials have been initiated to 
evaluate the clinical utility of PET in managing patients with NSCLC.
Conclusion: LDSG PGs have informed Ontario government funding 
decisions for chemotherapy drugs, inﬂuenced radiation therapy practice 
in Ontario cancer treatment centres and resulted in evaluative studies of 
PET technology. As well, through an updating process, they remain an 
excellent reference on current best practice that can be used by trainees 
and practitioners globally.
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Background: Recent data from both the National Cancer Institute of 
Canada (NCIC) and other studies has shown that early stage NSCLC 
patients receiving adjuvant chemotherapy after complete resection may 
have a signiﬁcant survival advantage as compared to surgery alone. The 
NCIC JBR10 study showed that 91% of patients receiving platinum-
based adjuvant chemotherapy experienced anemia, with 38% being 
grade 2 or higher. It is well known that platinum-based chemotherapy 
causes anemia. Subsequent exploratory analyses to this study docu-
menting the rate of anemia in the adjuvant NSCLC patient population 
and assessing impact on outcomes demonstrated that lower baseline 
